Literature DB >> 24833004

Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art.

Lucia Gastaldi1, Luigi Battaglia2, Elena Peira1, Daniela Chirio1, Elisabetta Muntoni1, Ilaria Solazzi1, Marina Gallarate1, Franco Dosio1.   

Abstract

Central nervous system disorders are already prevalent and steadily increasing among populations worldwide. However, most of the pharmaceuticals present on world markets are ineffective in treating cerebral diseases, because they cannot effectively cross the blood brain barrier (BBB). Solid lipid nanoparticles (SLN) are nanospheres made from biocompatible solid lipids, with unique advantages among drug carriers: they can be used as vehicles to cross the BBB. This review examines the main aspects surrounding brain delivery with SLN, and illustrates the principal mechanisms used to enhance brain uptake of the delivered drug.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Bioavailability; Biodistribution; Blood brain barrier; Central nervous system; Solid lipid nanoparticles

Mesh:

Substances:

Year:  2014        PMID: 24833004     DOI: 10.1016/j.ejpb.2014.05.004

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  35 in total

1.  The in vivo toxicological profile of cationic solid lipid nanoparticles.

Authors:  Monique Culturato Padilha Mendonça; Allan Radaic; Fernanda Garcia-Fossa; Maria Alice da Cruz-Höfling; Marco Aurélio Ramirez Vinolo; Marcelo Bispo de Jesus
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

Review 2.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

3.  Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?

Authors:  Christopher J Donnelly; Jonathan C Grima; Rita Sattler
Journal:  Neurodegener Dis Manag       Date:  2014

4.  Formulation and evaluation of rutin-loaded solid lipid nanoparticles for the treatment of brain tumor.

Authors:  Sureshbabu Ram Kumar Pandian; Parasuraman Pavadai; Sivakumar Vellaisamy; Vigneshwaran Ravishankar; Ponnusamy Palanisamy; Lakshmi M Sundar; Vivek Chandramohan; Murugesan Sankaranarayanan; Theivendren Panneerselvam; Selvaraj Kunjiappan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-06       Impact factor: 3.000

Review 5.  Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.

Authors:  Catherine DeMarino; Angela Schwab; Michelle Pleet; Allison Mathiesen; Joel Friedman; Nazira El-Hage; Fatah Kashanchi
Journal:  J Neuroimmune Pharmacol       Date:  2016-07-02       Impact factor: 4.147

6.  Rutin-Loaded Solid Lipid Nanoparticles: Characterization and In Vitro Evaluation.

Authors:  Federica De Gaetano; Maria Chiara Cristiano; Valentina Venuti; Vincenza Crupi; Domenico Majolino; Giuseppe Paladini; Giuseppe Acri; Barbara Testagrossa; Alessia Irrera; Donatella Paolino; Silvana Tommasini; Cinzia Anna Ventura; Rosanna Stancanelli
Journal:  Molecules       Date:  2021-02-16       Impact factor: 4.411

7.  Development and Statistical Optimization of Solid Lipid Nanoparticle Formulations of Fluticasone Propionate.

Authors:  Gülin Amasya; Ceyda Tuba Şengel TÜrk; Ulya Badilli; Nilüfer Tarimci
Journal:  Turk J Pharm Sci       Date:  2020-08-28

Review 8.  Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence.

Authors:  Lide Arana; Lucia Gallego; Itziar Alkorta
Journal:  Nanomaterials (Basel)       Date:  2021-05-10       Impact factor: 5.076

9.  Endocytic Uptake of Solid Lipid Nanoparticles by the Nasal Mucosa.

Authors:  Ammar S Al Khafaji; Maureen D Donovan
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

10.  Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation.

Authors:  Ahmed M Fatouh; Ahmed H Elshafeey; Ahmed Abdelbary
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.